Instil Bio, Inc. (TIL) Stock Price & Analysis
Instil Bio, Inc. (TIL) — MoonshotScore 34/100 (Weak band), calculated Nov 22, 2026. Price $5.23 (-5.77%), as of the Nov 20, 2026 trading session; market cap $35.5M.
Educational signal · not a buy or sell recommendation · How to read this
Instil Bio, Inc. · TIL · NASDAQ
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer treatment.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Instil Bio (TIL)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet and a full valuation, though quality is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Quiet.
- EPS beat 2 of the last 8 reports
- Altman Z -5.11 · Piotroski F 1
- ROE -26.8% · ROA -15.3% · current ratio 21.67 · earnings yield -73.4% · free-cash-flow yield -57.3%
Holding back: balance-sheet strain
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak |
The score moved from 33 in the stored Nov 21, 2026 snapshot to 34 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Momentum +4 and Financial Safety +1. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $5.23 | |
| Change on the day | -5.77% | |
| 52-week range | $5.23 – $14.54 | |
| Market capitalisation | $35.5M | — |
| Shares traded on the day | 64.3K |
Price & events
Other perspectives
Council score for Instil Bio (TIL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Instil Bio (TIL), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Instil Bio, Inc. (TIL) is listed on NASDAQ. It employs 17 people and is led by Bronson Crouch. The market values it at $35.5M.
What do the latest results show for Instil Bio (TIL)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of the last 8 reports.
What are the financial strengths and risks for Instil Bio (TIL)?
Short answer · as of
What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -5.11 · Piotroski F 1. Trailing ratios: ROE -26.8% · ROA -15.3% · current ratio 21.67 · earnings yield -73.4% · free-cash-flow yield -57.3%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -5.11 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-26.8%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
What should you watch next at Instil Bio (TIL)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $3.98M · EPS -2.23 · 1 analysts. The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for TIL.
Checked against the records this page reads, on the dates shown above.
How does Instil Bio compare with its peers?
Short answer
Instil Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.09 Nov 20, 2026 | $462M | 92 5-pillar Nov 22, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 22, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 22, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 87 5-pillar Nov 22, 2026 | |
| $15.47 Nov 20, 2026 | $83.3M | 82 5-pillar Nov 22, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 22, 2026 | |
| $3.57 Nov 20, 2026 | $155M | 72 5-pillar Nov 22, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 70 5-pillar Nov 22, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 22, 2026 | |
| $10.02 Nov 20, 2026 | $148M | 61 5-pillar Nov 22, 2026 | |
| $5.08 Nov 20, 2026 | $193M | 61 5-pillar Nov 22, 2026 | |
| $8.34 Nov 20, 2026 | $250M | 61 5-pillar Nov 22, 2026 | |
| Instil Bio (TIL) — this page | $5.23 | $35.5M | 34 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $7.00 – $7.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $7.00
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $7.00
- Revenue estimate
- $3.98M
- EPS estimate
- $-2.23
Historical target record · Captured · Capture expired; not a current watchpoint.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TIL in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TIL in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Instil Bio (TIL)?
Instil Bio Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for TIL?
TIL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is TIL a good stock to buy?
Stock Expert AI does not rate TIL buy, sell or hold. Instil Bio, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TIL stock price today?
The last price recorded for Instil Bio, Inc. (TIL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TIL price target?
The last analyst consensus price target we captured for Instil Bio, Inc. (TIL), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the key factors to evaluate for TIL?
Instil Bio, Inc. (TIL) holds a MoonshotScore in the low range. Instil Bio's approach involves isolating, expanding, and infusing TILs back into the patient to target and destroy cancer cells. Not financial advice.
How frequently does TIL data refresh on this page?
TIL's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TIL's recent stock price performance?
Instil Bio, Inc. (TIL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel TIL therapy platform with the potential to address unmet needs in cancer treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TIL overvalued or undervalued right now?
Instil Bio, Inc. (TIL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of TIL?
Fractional-share availability for Instil Bio, Inc. (TIL) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 7 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com